Recent research demonstrate that early molecular response to tyrosine-kinase inhibitors is normally strongly predictive of outcome in chronic myeloid leukemia individuals which early response landmarks may identify individuals at higher risk for transformation who benefit from an early on switch to second-line therapy. potential change Balicatib of therapy as soon as possible. We examined this… Continue reading Recent research demonstrate that early molecular response to tyrosine-kinase inhibitors is